Special section on survival finds significant improvement for all but two cancer sites. Bethesda, Maryland–(ENEWSPF)–March 31, 2017. Overall cancer death rates continue to decrease in men, women, and children for all major racial and ethnic groups, according to the latest Annual Report to the Nation on the Status of Cancer,[Read More…]
Health and Fitness
DEA To Classify Liquid, Synthetic THC As A Schedule II Controlled Substance
Washington, DC–(ENEWSPF)–March 30, 2017. Officials from the US Drug Enforcement Administration (DEA) have recommended that Syndros, a liquid form of synthetic THC, be classified as a Schedule II controlled substance under federal law. Food and Drug Administration (FDA) officials determined last year that the drug formulation is safe and effective[Read More…]
Multistate Outbreak of Shiga Toxin-producing E. coli Infections Linked to I.M. Healthy Brand SoyNut Butter
Atlanta, GA–(ENEWSPF)–March 30. 2017 What’s New Six more sick people have been reported since the last update on March 21, 2017. The most recent illness started on March 13, 2017. Two more people were hospitalized with hemolytic uremic syndrome (HUS), a type of kidney failure. The total is 29 sick[Read More…]
FDA URGENT NEWS: Envy Me Is Recalling LaBri’s Body Health Atomic 60 Capsules Due To Undeclared Sibutramine
Silver Spring, Maryland–(ENEWSPF)–March 30, 2017. Envy Me is recalling LaBri’s Body Health Atomic, dietary supplement marketed for weight loss, sold in 60 capsule, plastic bottles. The recall includes all lot codes, manufacturing codes and expiration dates. The United States Food and Drug Administration has analyzed samples of La Bri’s Body[Read More…]
FDA Approves New Drug to Treat Multiple Sclerosis
First drug approved for Primary Progressive MS Silver Spring, Maryland–(ENEWSPF)–March 30, 2017. On March 28, the U.S. Food and Drug Administration approved Ocrevus (ocrelizumab) to treat adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS). This is the first drug approved by the FDA[Read More…]
FDA Approves New Eczema Drug Dupixent
Silver Spring, Maryland–(ENEWSPF)–March 28, 2017. The U.S. Food and Drug Administration today approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis). Dupixent is intended for patients whose eczema is not controlled adequately by topical therapies, or those for whom topical therapies are not advisable. Dupixent can be[Read More…]
FDA Approves Maintenance Treatment for Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancers
Silver Spring, Maryland–(ENEWSPF)–March 27, 2017. The U.S. Food and Drug Administration today approved Zejula (niraparib) for the maintenance treatment (intended to delay cancer growth) of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk (complete or partial response, respectively) in[Read More…]
Study: Regular Cannabis Use Associated With Lower BMI, No Adverse Effect On Bone Density
Portland, OR–(ENEWSPF)–March 23, 2017. Those subjects who consume cannabis more than five times per month possess, on average, lower body mass index (BMI) than do those who do not use the substance, according to data published online ahead of print in the journal Archives of Osteoporosis. Researchers at Oregon’s Health[Read More…]
Senator Duckworth, Veterans in Congress Criticize Trumpcare’s Devastating Tax Hike on Millions of Veterans
WASHINGTON, DC —(ENEWSPF)–March 23, 2017. Today, combat Veteran and U.S. Senator Tammy Duckworth (D-IL) joined Ranking Member of the Senate Armed Services Committee Jack Reed (D-RI), Ranking Member of the House Committee on Veterans’ Affairs Tim Walz (D-MN), and several others to criticize President Trump and his Republican allies in[Read More…]
FDA Approves First Treatment for Rare Form of Skin Cancer
Source: flickr.com Silver Spring, Maryland–(ENEWSPF)–March 23, 2017. The U.S. Food and Drug Administration today granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy. This is the first[Read More…]
